Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OPK, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Calcifediol | Secondary Hyperparathyroidism Due to Renal Causes | Phase 4 · NCT03588884 | Completed |
| Calcifediol Oral Product | Secondary Hyperparathyroidism Due to Renal Causes | Phase 4 · NCT03588884 | Completed |
| Cholecalciferol | Secondary Hyperparathyroidism Due to Renal Causes | Phase 4 · NCT03588884 | Completed |
| Bevasiranib | Age Related Macular Degeneration | Phase 3 · NCT00557791 | Withdrawn |
| Somatrogon | Pediatric Growth Hormone Deficiency | Phase 3 · NCT02968004 | Completed |
| Modified-release Calcifediol Capsule (CTAP101) | Chronic Kidney Disease | Phase 3 · NCT02282813 | Completed |
| Cohort 2 Matching Sugar Capsule | Chronic Kidney Disease | Phase 2/3 · NCT01219855 | Completed |
| Cohort 2 CTAP101 Capsules - 30µg | Chronic Kidney Disease | Phase 2/3 · NCT01219855 | Completed |
| Cohort 1 Matching Sugar Capsule | Chronic Kidney Disease | Phase 2/3 · NCT01219855 | Completed |
| Cohort 1 CTAP101 Capsules- 60µg | Chronic Kidney Disease | Phase 2/3 · NCT01219855 | Completed |
| Cohort 1 CTAP101 Capsules - 90µg | Chronic Kidney Disease | Phase 2/3 · NCT01219855 | Completed |
| OPK-88006 | MASH | Phase 1/2 · NCT07512427 | Recruiting |
| OPK-88003 | Type 2 Diabetes Mellitus | Phase 2 · NCT03406377 | Completed |
| Metformin | Diabetes Mellitus, Type 2 | Phase 2 · NCT02119819 | Completed |
| MDX2004 | Advanced Tumors | Phase 1/2 · NCT07110584 | Recruiting |
| MDX2003 | Lymphoma | Phase 1/2 · NCT07249905 | Recruiting |
Also used in these trials (approved or third-party drugs, not OPK's own candidates): Paricalcitol, Somatropin, Ranibizumab, Doxercalciferol, Calcitriol, Valproic Acid, Lamotrigine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OPK holds $384M in cash and short-term investments (as of Sep 30, 2026) and burns about $39.9M/quarter from operations, an estimated runway of 28.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OPK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Frost Phillip Md Et Al CEO & Chairman, Director, 10% owner · +500,000 options |
Insider | 255,429,406 | 34.40% | 2026-06-29 |
| Steven D Rubin Executive VP-Administration, Director · +437,500 options |
Insider | 6,571,966 | 0.89% | 2026-07-24 |
| OPKO HEALTH, INC. | 5%+ holder (13D) | 5,692,916 | 0.77% | 2026-11-04 |
| Subbarao V Uppaluri Director · +130,000 options |
Insider | 1,158,817 | 0.16% | 2026-03-18 |
| Adam Logal Sr. Vice President, CFO · +437,500 options |
Insider | 563,396 | 0.08% | 2026-07-24 |
| John A Paganelli Director · +60,000 options |
Insider | 389,914 | 0.05% | 2026-11-05 |
Share count 742,506,477 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OPK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →